Clinical Trial Update: A Comparison of Prostaglandin E2 (PGE2) Inhibition of Acuvail(Ketorolac 0.45%), Xibrom (Bromfenac 0.09%)and Nevanac (Nepafenac)in Patients Undergoing Phacoemulsification [Phase 4]

View source ↗

Summary

Phase 4 clinical trial comparing the prostaglandin E2–inhibiting effects of Acuvail (ketorolac 0.45%), Xibrom (bromfenac 0.09%), and Nevanac (nepafenac) in pati…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cataract

Drugs mentioned

• ACUVAIL (ketorolac tromethamine)
• Nevanac (nepafenac)
• Xibrom (bromfenac)

Snippet

Sponsor: Frank A. Bucci, Jr., M.D. | Conditions: Cataracts | Phase 4 | Status: COMPLETED | Results posted: 2011-08-26